Resultaterne af disse undersøgelser vil danne grundlaget for den årlige revurdering af risk/ benefit- forholdet.
Actelion commits to continue the comprehensive Zavesca Post-Marketing Surveillance Plan (PMSP) in the EU, which will educate prescribers on the appropriate use of Zavesca and